abrdn plc Purchases 62,776 Shares of IQVIA Holdings Inc. (NYSE:IQV)

abrdn plc raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 138.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 108,151 shares of the medical research company’s stock after buying an additional 62,776 shares during the quarter. abrdn plc’s holdings in IQVIA were worth $25,024,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of IQV. AdvisorNet Financial Inc boosted its position in IQVIA by 327.6% during the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 95 shares during the last quarter. BKM Wealth Management LLC bought a new stake in IQVIA during the fourth quarter valued at $32,000. Activest Wealth Management bought a new stake in IQVIA during the fourth quarter valued at $35,000. CVA Family Office LLC bought a new stake in IQVIA during the fourth quarter valued at $43,000. Finally, CoreFirst Bank & Trust bought a new stake in IQVIA during the third quarter valued at $44,000. Institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric Sherbet sold 1,000 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the transaction, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,285 shares of company stock worth $10,331,003. Insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

IQV has been the topic of several research reports. BTIG Research initiated coverage on shares of IQVIA in a report on Tuesday, February 13th. They set a “buy” rating and a $285.00 price objective on the stock. Guggenheim lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Truist Financial upped their price objective on shares of IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Finally, SVB Leerink initiated coverage on shares of IQVIA in a report on Monday, February 26th. They set an “outperform” rating and a $290.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $256.80.

IQVIA Trading Up 3.2 %

IQV opened at $238.74 on Wednesday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. The firm has a market capitalization of $43.33 billion, a PE ratio of 32.75, a P/E/G ratio of 2.24 and a beta of 1.50. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company’s 50-day moving average is $245.55 and its 200 day moving average is $222.56.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.82 by $0.02. The firm had revenue of $3.87 billion during the quarter, compared to analyst estimates of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter last year, the business posted $2.54 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.